Cite
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience
MLA
Rossella Iula, et al. “Efficacy and Safety of Belantamab-Mafodotin in Triple-Refractory Multiple Myeloma Patients: A Multicentric Real-Life Experience.” Frontiers in Oncology, vol. 12, Nov. 2022. EBSCOhost, https://doi.org/10.3389/fonc.2022.1026251.
APA
Rossella Iula, Danilo De Novellis, Fabio Trastulli, Roberta Della Pepa, Raffaele Fontana, Angela Carobene, Maria Di Perna, Alessandro D’Ambrosio, Martina Romano, Aldo Leone, Laura De Fazio, Alfonso Fiumarella, Giuseppe Gaeta, Violetta Marafioti, Serafina Barbato, Salvatore Palmieri, Stefano Rocco, Bianca Serio, Catello Califano, … Lucio Catalano. (2022). Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1026251
Chicago
Rossella Iula, Danilo De Novellis, Fabio Trastulli, Roberta Della Pepa, Raffaele Fontana, Angela Carobene, Maria Di Perna, et al. 2022. “Efficacy and Safety of Belantamab-Mafodotin in Triple-Refractory Multiple Myeloma Patients: A Multicentric Real-Life Experience.” Frontiers in Oncology 12 (November). doi:10.3389/fonc.2022.1026251.